Welcome to the e-CCO Library!

P364: The value of faecal calprotectin for assessing endoscopic activity and predicting future clinical course in patients with active ulcerative colitis treated with granulomonocytapheresis: a prospective study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

T. Shimoyama*1, T. Yamamoto1, S. Umegae1, K. Matsumoto1

Created: Friday, 22 February 2019, 9:41 AM
P365 Identification of predictive factors of AZA/6-MP treatment outcome in paediatric luminal Crohn’s disease: a multicentre study of the paediatric IBD Porto group of ESPGHAN
Year: 2020
Source:

ECCO'20 Vienna

Authors:

T. LERCHOVA1, O. Hradsky1, M. Kulich2, G. Veres3, J.A. Dias4, M. Sladek5, S. Kolacek6, S. Van Biervliet7, J. Melek8, D. Serban9, K. Winther10, T. de Meij11, J. Schwarz12, K.L. Kolho13, J.C. Escher14, J. Bronsky1

Created: Thursday, 30 January 2020, 10:12 AM
P365: Autologous haematopoietic stem cell transplantation in refractory Crohn’s disease: experience of a Brazilian tertiary centre
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Oba*1,2, F. Steinwurz2, A. Scanavini Neto3, O. Ambrogini4, C. Silva5, S. Nakashima5, M. Santos5, N. Hamerschlak6

Created: Friday, 22 February 2019, 9:41 AM
P365: Biological interventions for induction and maintenance of mucosal healing in Crohn’s disease: A Cochrane systematic review
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Ricciuto1*, P. Church1, M.J. Stewart2, H.H. Shim2, M. Storr3,4, R. Panaccione2, A. Griffiths1, C. Seow2

Created: Thursday, 21 February 2019, 9:14 AM
P365: Correlation between patient-reported outcomes (PROs) and patient-reported disease activity in Ulcerative Colitis (UC): Findings from the ICONIC study
Year: 2021
Source: ECCO'21 Virtual
Authors: Ghosh, S.(1);Casellas, F.(2);Kligys, K.(3);Sanchez Gonzalez, Y.(4);Peyrin-Biroulet, L.(5);
Created: Wednesday, 2 June 2021, 4:12 PM
P365: Psoriasis in Inflammatory Bowel Disease: Comparison of Extraintestinal Manifestations and Effect of Anti-TNF Therapies
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Kilic, D.T.(1);Yuksel, I.(1,2)*;
Created: Friday, 14 July 2023, 11:05 AM
P365: Real-world effectiveness of adalimumab in patients with ulcerative colitis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A. Armuzzi*1, C. Taxonera2, J. Panes3, P. Lakatos4, N. Fisseha5, B. Pappalardo5

Created: Friday, 22 February 2019, 9:49 AM
P365: Serum adalimumab levels predict successful remission and safe de-intensification in inflammatory bowel disease patients in clinical practice
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Aguas M.*1,2, Bosό V.3, Navarro B.1, Marqués-Miñana M.R.3, Bastida G.1,2, Beltrán B.1,2, Iborra M.1,2, Monte-Boquet E.3, Poveda-Andrés J.L.3, Nos P.1,2

Created: Wednesday, 20 February 2019, 10:36 AM
P365: Weight gain after initiation of adalimumab in patients with Crohn’s disease
Year: 2022
Source: ECCO'22
Authors: Darwin, L.(1);Wall, C.(2);Su, H.(1);Gearry, R.B.(2);
Created: Friday, 11 February 2022, 3:52 PM
P366 CRP levels and PMS as early predictors of clinical and endoscopic outcomes in adult patients with moderately-to-severely active UC treated with tofacitinib: a post hoc analysis of OCTAVE Induction 1 and 2
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M.C. Dubinsky1, D.P. Hudesman2, F. Steinwurz3, N. Kulisek4, L. Salese4, J. Paulissen5, C. Su4, D. Ponce de Leon6, F. Magro7

Created: Thursday, 30 January 2020, 10:12 AM
P366: A service evaluation of pre-operative nutritional optimisation in patients with Crohn’s disease using exclusive enteral nutrition with or without supplementary parenteral nutrition
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

D. O'Hanlon1, A. Sandall1,2, A. Darakhshan3, A. Williams3, E. Westcott3, K. Patel4, P. Irving4, M. Lomer1,2

Created: Friday, 22 February 2019, 9:41 AM
P366: Escherichia coli Nissle 1917 in ulcerative colitis treatment: systematic review and meta-analysis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

G. Losurdo*, A. Iannone, A. Contaldo, E. Ierardi, A. Di Leo, M. Principi

Created: Friday, 22 February 2019, 9:49 AM
P366: Exclusive enteral nutrition drives protective microbiome modulation in paediatric Crohn's Disease
Year: 2022
Source: ECCO'22
Authors: Häcker, D.(1);Siebert, K.(2);Metwaly, A.(1);Hölz, H.(2);De Zen, F.(2);Köhler, N.(3);Pauling, J.K.(3);Matchado, M.(4);List, M.(4);Schwerd, T.(2);Haller, D.(1,5);
Created: Friday, 11 February 2022, 3:52 PM
P366: genomics analysis and differentiation of Crohn's Disease, Intestinal Tuberculosis and Primary Intestinal Iymphoma
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Lin, L.(1)*;Qu, Y.(2);Zhao, X.(1);
Created: Friday, 14 July 2023, 11:05 AM
P366: Long-term evolution of gastrointestinal immune-related adverse events (GI-IrAE) induced by immune checkpoint inhibitors (ICI)
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. de Malet1*, G. Antoni2, E. Soularue1, M. Collins1, L. Marthey1, T. Vaysse1, C. Mateus3, C. Robert3, F. Carbonnel1

Created: Thursday, 21 February 2019, 9:14 AM
P366: The efficacy of vedolizumab for induction of clinical response and remission in anti-TNF naïve patients with inflammatory bowel disease – a multicenter European real world experience
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Kopylov U.*1, Sebastian S.2, Ron Y.3, Steinhagen P.R.4, Roblin X.5, Pugliese D.6, Bar-Gil Shitrit A.7, Katsanos K.8, Fiorino G.9, Allocca M.10, Sipponen T.11, Ungar B.12, Armuzzi A.6, Eliakim R.12, Christodoulou D.8, Baumgart D.C.4, Ben-Horin S.12, Dotan I.3

Created: Wednesday, 20 February 2019, 10:36 AM
P366: Vedolizumab maintenance therapy reduced use of corticosteroids in patients with Crohn’s disease in the GEMINI 2 trial
Year: 2021
Source: ECCO'21 Virtual
Authors: D'Haens, G.(1);Candela, N.(2);Uddin, S.(3);Peterson, T.(2);Dubinsky, M.(4);Colombel, J.F.(5);
Created: Wednesday, 2 June 2021, 4:12 PM
P367 Real-life long-term effectiveness and treatment persistence of vedolizumab in a single tertiary care cohort of Crohn’s disease patients
Year: 2020
Source:

ECCO'20 Vienna

Authors:

L. Calandrini, M. Salice, H. Privitera Hrustemovic, G. Peruzzi, F. Rizzello, C. Calabrese, E. Scaioli, A. Belluzzi, P. Gionchetti

Created: Thursday, 30 January 2020, 10:12 AM
P367: Lower quality of life, more active disease and increased healthcare costs due to non-adherence in inflammatory bowel disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Severs*1, M.-J. Mangen2, H. H. Fidder1, M. E. van der Valk1, M. van der Have1, A. A. van Bodegraven3, 4, C. H. M. Clemens5, G. Dijkstra6, J. M. Jansen7, D. J. de Jong8, N. Mahmmod9, P. C. van de Meeberg10, A. E. van der Meulen- de Jong11, M. Pierik12, C. Y. Ponsioen13, M. J. L. Romberg- Camps3, P. D. Siersema1, J. R. Vermeijden14, J. van der Woude15, P. N. Zuithoff16, B. Oldenburg1

Created: Friday, 22 February 2019, 9:49 AM
P367: Nutrition advice for IBD patients as a useful complementary strategy: a single-centre cohort intervention
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Fortuna1, M. Di Ruscio*1, A. Variola1, A. Massella1, A. Geccherle1

Created: Friday, 22 February 2019, 9:41 AM